Evidence map›Paper›PMID 39462367›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2024

A case report of fatal anaphylaxis on first exposure to rasburicase just before lymphoma treatment.

Yoshikazu Utsu, Natsuho Kaneda, Makio Kawakami, Shin-Ichi Masuda, Hironori Arai, Sonoko Shimoji, Rena Matsumoto, Takafumi Tsushima, Kazusuke Tanaka, Kosuke Matsuo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yoshikazu UtsuDepartment of Medical Oncology, Japanese Red Cross Narita Hospital, 90-1, Iida-Cho, Narita, 286-8583, Japan. yutsu@naritasekijyuji.jp.ORCID http://orcid.org/0000-0002-3836-3216
Natsuho KanedaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Makio KawakamiDepartment of Pathology, Japanese Red Cross Narita Hospital, Narita, Japan.
Shin-Ichi MasudaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Hironori AraiDepartment of Medical Oncology, Japanese Red Cross Narita Hospital, 90-1, Iida-Cho, Narita, 286-8583, Japan.
Sonoko ShimojiDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Rena MatsumotoDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Takafumi TsushimaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Kazusuke TanakaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Kosuke MatsuoDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Chiharu KimedaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Shiho KonnoDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Nobuyuki AotsukaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRasburicase, a recombinant urate oxidase enzyme, has potent efficacy in controlling uric acid and is widely used to prevent tumor lysis syndrome in high-risk patients owing to its low toxicity profile. However, it has been associated with a risk of anaphylaxis, especially on re-exposure, owing to its immunogenic potential. CASE PRESENTATION: A 71-year-old Japanese female diagnosed with diffuse large B cell lymphoma with a large tumor burden experienced anaphylactic shock leading to death upon initial administration of rasburicase. The pre-and postmortem examination revealed that the cause of death was a cascade of events starting with anaphylaxis-induced distributive shock leading to obstructive shock due to the collapse of the heart, which was compressed by the post-mediastinal tumor. This was further compounded by massive bleeding from the tumor and tension hemothorax, resulting in circulatory collapse.

conclusionsAlthough extremely rare, rasburicase can cause fatal anaphylaxis, even on first exposure.

Indexed as

AllergyAnaphylaxisAsthmaDeathFatalInitial administrationLymphomaRasburicaseShock

Identifiers

PMID39462367
PMCPMC11514887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.